by Richard Smith Health Fitness Specialist

“Bipolar disorder is a leading cause of disease burden in the pediatric population both here in the US and across the globe, but unfortunately, few treatments are effective in treating young people living with the condition,’ Robert Findling, Director of child and adolescent psychiatry, commented in the release.”

The new medication Lurasidone (Latuda) is approved as a medication for the treatment of bipolar depression. 

This drug is used to treat major depressive episodes for children aged 10 to 17 years who have bipolar depression. The US has already confirmed Lurasidone for treating adults facing bipolar depression.

According to the statistics, Lurasidone was considered to make significant improvements in the symptoms of bipolar depression as compared to placebo. You may find certain issues post-treatment state such as nausea, gaining weight and insomnia.

Robert Findling also stated that the students who are treated by using this medication may have the risk of poor school performance and impaired school learning. 

The approval of Lurasidone (Latuda) to treat pediatric patients facing bipolar depression is important for various reasons. 

Firstly, it is said to be a new treatment for the people of young age. It is one of the first single-agent formulations to receive regulatory approval for the treatment.

Sponsor Ads

About Richard Smith Innovator   Health Fitness Specialist

19 connections, 0 recommendations, 63 honor points.
Joined APSense since, July 11th, 2019, From Brookline MA, United States.

Created on Aug 28th 2019 15:13. Viewed 481 times.


No comment, be the first to comment.
Please sign in before you comment.